Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| Tafasitamab | ENANTA PHARMACEUTICALS INC (ENTA) |
Frequently asked questions
How many drugs are in development for Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder?
BioSniper tracks 1 drug in development for Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder across 1 company.
How many clinical trials target Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder?
There are 1 clinical trial targeting Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder tracked by BioSniper.
Deep-dive into Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis